Changes in endorphins and 5-hydroxyindoleacetic acid in cerebrospinal fluid as a result of treatment with a serotonin reuptake inhibitor (zimelidine) in chronic pain patients |
| |
| Authors: | F Johansson L von Knorring G Sedvall L Terenius |
| |
| Affiliation: | 1. Folke Johansson, M.D., is Senior Neurologist, Department of Neurology, University of Umeå, Sweden;2. Lars von Knorring, M.D., is Associate Profesor, Department of Psychiatry, University of Umeå, Sweden;3. Göran Sedvall, M.D., is Professor, Department of Psychiatry, Karolinska Hospital, Stockholm, Sweden;4. Lars Terenius, M.D., is Professor, Department of Pharmacology, University of Uppsala, Sweden |
| |
| Abstract: | Both the endorphin and the serotonin systems seem to be involved in pain perception, and a significant positive correlation between the levels of endorphins and 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) has been established. In the present study, 20 chronic pain patients were treated with zimelidine, a rather selective inhibitor of serotonin reuptake, or placebo. Zimelidine produced a significant pain relief and a significant reduction of the levels of endorphins and 5-HIAA in CSF, while no significant changes occurred during placebo treatment. The results indicate that both the endorphin and the serotonin systems are involved in pain perception and that the systems are functionally related. |
| |
| Keywords: | Chronic pain endorphins 5-hydroxyindoleacetic acid serotonin reuptake inhibitor |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
